Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Ginkgo Biloba vs Huperzine A: Ginkgo Biloba has the stronger overall evidence (7 vs 6/10); they're alternatives for sharpen focus — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Ginkgo Biloba wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
5 of 8 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Ginkgo Biloba and Huperzine A have evidence — compare verdict strength side-by-side.
120-240mg standardized extract
With meals, Split into 2-3 doses
Standardized extract capsules (EGb 761)
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
and 1 more not shown
12-24 weeks
8-12 weeks
First week
2-4 weeks
30-60 minutes
2-4 weeks
During use
Can We Use Ginkgo biloba Extract to Treat Alzheimer's Disease? Lessons from Preclinical and Clinical Studies
Cells (2022) · Meta analysis · n=2100
GBE was shown to reduce the escape latencies in several studies, in both rats and mice (I2 > 70%, p < 0.005).
Beneficial effects of Ginkgo biloba leaf extract on inflammatory markers: A systematic review and meta-analysis of the clinical trials
Phytotherapy research : PTR (2022) · Meta analysis · n=1104
In the meta-analysis, the weighted mean differences (WMD) in change for serum CRP were -1.5 mg/L (95% CI: -2.16, -0.85, p < 0.001).
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
The Cochrane database of systematic reviews (2018) · Meta analysis · n=1278
Studies were primarily of short (three to six6 weeks) duration with small samples size (10 to 157 participants), and most (61%) were published more than 20 years ago.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=70
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
The trials behind these points gave 120 or 240 mg of the standardised extract EGb 761 daily to people with dementia for about 6 months (PMID 25506211, 7 trials, 2,625 patients). A meta-analysis of 9 trials found the benefits on cognition, daily activities and global impression mainly at 240 mg (PMID 25114079), and one of mild dementia subgroups found medium to large effects at 240 mg (PMID 39895346). A network meta-analysis of trials lasting over a year ranked 120 mg best for cognition in Alzheimer's disease (PMID 39312316), so 120 mg is plotted as effective, not null. Adverse events matched placebo at both doses. The Cochrane review rates the dementia benefit small to moderate and low certainty, and found little or no effect in mild cognitive impairment (PMID 41641880). In older people with normal cognition, 240 mg a day for about 6 years did not prevent dementia (PMID 19017911). No cited trial tested more than 240 mg.
Doses are per day. At 200 mcg (0.1 mg twice daily), a double-blind trial in 78 people with mild to moderate vascular dementia improved MMSE, CDR and daily living scores over 12 weeks (PMID 21833673). At 400 mcg (200 mcg twice daily), the primary analysis of a phase II trial in 210 people with Alzheimer's disease found no effect on ADAS-Cog at 16 weeks, so the curve stays flat rather than rising (PMID 21502597). At 800 mcg (400 mcg twice daily), the same trial found a 2.27-point ADAS-Cog gain at 11 weeks that was no longer significant at 16 weeks. A meta-analysis of four trials using 300 to 500 mcg a day found MMSE and daily living gains (PMID 19221692). The trials are in different populations and only one compared doses, so no minimum, optimal or safe ceiling is set.
AI-estimated from published studies. Interpret as directional guidance.
Ginkgo Biloba has a higher evidence score (7/10 vs 6/10) and wins in 2 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 60).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.